These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 14740283)

  • 1. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline.
    Vansteenkiste J; Tomita D; Rossi G; Pirker R
    Support Care Cancer; 2004 Apr; 12(4):253-62. PubMed ID: 14740283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    Vansteenkiste J; Pirker R; Massuti B; Barata F; Font A; Fiegl M; Siena S; Gateley J; Tomita D; Colowick AB; Musil J;
    J Natl Cancer Inst; 2002 Aug; 94(16):1211-20. PubMed ID: 12189224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
    BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E;
    Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies.
    Hedenus M; Hansen S; Taylor K; Arthur C; Emmerich B; Dewey C; Watson D; Rossi G; Osterborg A;
    Br J Haematol; 2002 Oct; 119(1):79-86. PubMed ID: 12358906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa: in patients with chemotherapy-related anaemia.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(11):1067-74; discussion 1075-7. PubMed ID: 12749734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.
    Hedenus M; Adriansson M; San Miguel J; Kramer MH; Schipperus MR; Juvonen E; Taylor K; Belch A; Altés A; Martinelli G; Watson D; Matcham J; Rossi G; Littlewood TJ;
    Br J Haematol; 2003 Aug; 122(3):394-403. PubMed ID: 12877666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
    Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
    Vansteenkiste J; Poulsen E; Rossi G; Glaspy J
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):45-55. PubMed ID: 12435173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
    Gascón P; Nagarkar R; Šmakal M; Syrigos KN; Barrios CH; Sánchez JC; Zhang L; Henry DH; Gordon D; Hirsh V; Kubota K; Orlov S; Thomas G; Steinmetz T; Kang JH; Tomita DK; Fleishman AN; Park JK; De Oliveira Brandao C
    J Thorac Oncol; 2020 Feb; 15(2):190-202. PubMed ID: 31629060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF
    Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
    Gabrilove J; Paquette R; Lyons RM; Mushtaq C; Sekeres MA; Tomita D; Dreiling L
    Br J Haematol; 2008 Jul; 142(3):379-93. PubMed ID: 18540943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
    Esquerdo G; Llorca C; Cervera JM; Orts D; Juárez A; Carrato A
    Clin Transl Oncol; 2011 May; 13(5):341-7. PubMed ID: 21596663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.